Study Provides Insights on Asparaginase-Associated Pancreatitis in Pediatric ALL

Asparaginase, a key therapeutic for acute lymphoblastic leukemia (ALL), works by depleting asparagine, an amino acid essential for leukemia cell survival. However, a serious complication of this treatment is asparaginase-associated pancreatitis (AAP), which can cause pancreatic inflammation and interrupt cancer therapy. In a study published in Blood, Ching-Hon Pui, MD, St. Jude Department of Oncology, alongside international collaborators, analyzed the risk factors for developing AAP and assessed the outcomes and impact of asparaginase rechallenge—the reintroduction of the drug in patients who had previously experienced an adverse reaction. The study revealed that older age and intermediate- and high-risk disease status significantly increased the likelihood of developing AAP. Notably, it found that asparaginase rechallenge improved treatment outcomes in intermediate- and high-risk patients with AAP, but not in low-risk patients.

“This study is incredibly important for clinicians because every time a patient develops pancreatitis after receiving asparaginase, there’s significant uncertainty and concern about whether to rechallenge or not,” explained Pui. “This study provides clear guidance on when a rechallenge should be considered to avoid poor treatment outcomes.”

Read more